2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
Status:
Active, not recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This study will assess whether adding one of the newest multiple myeloma therapies,
daratumumab, into the Total Therapy approach helps patients live longer with fewer side
effects